Mechanisms of resistance to quinolones

GA Jacoby - Clinical infectious diseases, 2005 - academic.oup.com
The increased use of fluoroquinolones has led to increasing resistance to these
antimicrobials, with rates of resistance that vary by both organism and geographic region …

[HTML][HTML] Quinolones in 2005: an update

F Van Bambeke, JM Michot, J Van Eldere… - Clinical Microbiology …, 2005 - Elsevier
Quinolones are one of the largest classes of antimicrobial agents used worldwide. This
review considers the quinolones that are available currently and used widely in Europe …

Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms

XZ Li - International journal of antimicrobial agents, 2005 - Elsevier
Bacterial resistance to quinolones/fluoroquinolones has emerged rapidly and such
resistance has traditionally been attributed to the chromosomally mediated mechanisms that …

Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients

DH Kim, WJ Stark, TP O'Brien, JD Dick - Ophthalmology, 2005 - Elsevier
PURPOSE: To measure the achievable perioperative aqueous concentration of the
commercially available topically administered fourth generation fluoroquinolones …

Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol

N Rudenko, A Dorofeyev - Arzneimittelforschung, 2005 - thieme-connect.com
Three hundred and seventeen non pregnant females, suffering of recurrent lower urinary
tract infections (UTIs; at least three episodes in the preceding 12 months) were enrolled in a …

Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli

LL Marcusson, SK Olofsson, PK Lindgren… - Journal of …, 2005 - academic.oup.com
Objectives: To measure the mutant prevention concentration (MPC) of ciprofloxacin for a set
of urinary tract infection (UTI) Escherichia coli isolates with different levels of susceptibility …

In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone

DW Stroman, JJ Dajcs, GA Cupp, BA Schlech - Survey of ophthalmology, 2005 - Elsevier
Fluoroquinolones are a class of synthetic antibacterial agents that were approved for ocular
therapy in 1991 and have become popular therapy for the treatment and prevention of …

Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy

JP Lynch, GG Zhanel - Seminars in respiratory and critical care …, 2005 - thieme-connect.com
Over the past 2 decades, antimicrobial resistance among Streptococcus pneumoniae, the
most common cause of community-acquired pneumonia (CAP), has escalated dramatically …

Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance

HG Wetzstein - Antimicrobial agents and chemotherapy, 2005 - Am Soc Microbiol
ABSTRACT Pradofloxacin (PRA) is an 8-cyano-fluoroquinolone (FQ) being developed to
treat bacterial infections in dogs and cats. Its mutant prevention concentrations (MPC) were …

Pharmacodynamic Modeling of Ciprofloxacin Resistance in Staphylococcus aureus

JJ Campion, PJ McNamara… - Antimicrobial agents and …, 2005 - Am Soc Microbiol
Three pharmacodynamic models of increasing complexity, designed for two subpopulations
of bacteria with different susceptibilities, were developed to describe and predict the …